220634-41-3

Basic information

• Product Name: (2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine(SALTDATA: HCl)
• Synonyms: (2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine(SALTDATA: HCl);4-AMino-3,4-dihydro-2,2-diMethyl-2H-1-benzopyran;(2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine;2,2-dimethyl-4-chromanamine;2,2-dimethylchroman-4-amine
• CAS NO: 220634-41-3
• Molecular Formula: C₁₁H₁₅NO
• Molecular Weight: 177.2429
• Mol File: 220634-41-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: (2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine(SALTDATA: HCl)(220634-41-3)
• EPA Substance Registry System: (2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine(SALTDATA: HCl)(220634-41-3)

Safety Data

• Hazardous Substances Data: 220634-41-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine(SALTDATA: HCl) is utilized as a pharmaceutical candidate for the development of new drugs. Its unique chemical structure and potential biological activity make it a promising compound for the treatment of various medical conditions.
Used in Medicinal Purposes:
In the medical field, (2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine(SALTDATA: HCl) is used as a therapeutic agent. The HCl salt form allows for better solubility and stability, which can enhance its effectiveness in treating specific medical conditions.
Researchers continue to explore the potential applications of (2,2-dimethyl-3,4-dihydro-2H-chromen-4-yl)amine in the treatment of various medical conditions, as its unique properties and potential biological activity make it a valuable compound for further investigation and development.

Upstream product

• 3780-33-4 2,3-dihydro-2,2-dimethylbenzo[b]pyran-4-one 
• 24700-17-2 3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-hydroxyimine 
• 1072930-94-9 4-azido-2,2-dimethyl-3,4-dihydro-2H-chromene 

Downstream Products

• 1042679-29-7 C₁₈H₁₉ClN₂O₂ 
• 1042679-30-0 C₁₈H₁₉ClN₂O₂ 

Relevant articles and documents

CHROMANE DERIVATIVES AS TRPV3 MODULATORS

The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are pro

Synthesis and activity on rat aorta rings and rat pancreatic β-cells of ring-opened analogues of benzopyran-type potassium channel activators

Ring-opened analogues of dihydrobenzopyran potassium channel openers (PCOs) were prepared and evaluated as putative PCOs on rat aorta rings (myorelaxant effect) and rat pancreatic β-cells (inhibition of insulin secretion). These derivatives are characterized by the presence of a sulfonylurea, a urea or an amide function. Some compounds bearing an arylurea moiety provoked vasorelaxant effects and a marked inhibition of insulin release. Derivatives bearing a sulfonylurea or an amide function were, however, poorly active on both tissues. Structure-activity relationships and apparent tissue selectivity are discussed.

ISOQUINOLINE DERIVATIVES AS VANILLOID RECEPTOR MODULATORS

The present invention relates to substituted isoquinoline derivatives of formula I, which can be used as vanilloid receptor ligands, methods of treating diseases, condition and/or disorders modulated by vanilloid receptors with them, and processes for preparing them.

1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use

Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulas ( I ) and ( II ).